CDS008318
(4S)-4,11-二乙基-4,9-二羟基-1H-吡喃酮[3′,4′:6,7]中氮茚[1,2-b]喹啉-3,14(4H,12H)二酮
AldrichCPR
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H20N2O5
化学文摘社编号:
分子量:
392.40
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
InChI
1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
SMILES string
CCc1c2CN3C(=O)C4=C(C=C3c2nc5ccc(O)cc15)[C@@](O)(CC)C(=O)OC4
InChI key
FJHBVJOVLFPMQE-QFIPXVFZSA-N
form
solid
Other Notes
请注意，Sigma-Aldrich将本品作为一系列特殊化学品的一部分提供给早期发现研究人员。Sigma-Aldrich不收集本品的分析数据。买方承担确认产品特性和/或纯度的责任。所有销售均为最终销售。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 1B - STOT RE 1
target_organs
Gastro-intestinal system
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Céline Chu et al.
Fundamental & clinical pharmacology, 28(6), 652-660 (2014-03-05)
In a previous study, we showed that cetuximab, a monoclonal antibody directed towards epidermal growth factor receptor, could inhibit P-glycoprotein (P-gp), an efflux protein of ATP-binding cassette family, and lead to an increased P-gp substrate intracellular concentration. Cetuximab is given
Hiroaki Ozasa et al.
Cancer science, 105(8), 1032-1039 (2014-05-16)
The c-MET receptor tyrosine kinase is the receptor for hepatocyte growth factor. Recently, activation of the c-MET/hepatocyte growth factor signaling pathway was associated with poor prognosis in various solid tumors and was one of the mechanisms of acquired resistance to
Gabriela Gajek et al.
Molecules (Basel, Switzerland), 25(3) (2020-02-09)
The incidence of gastrointestinal cancers is increasing every year. Irinotecan (CPT-11), a drug used in the treatment of colorectal cancer and gastric cancer, is metabolized by carboxylesterases to an active metabolite, SN-38, which is more cytotoxic. CAPE (caffeic acid phenethyl
Jian Yu et al.
Phytotherapy research : PTR, 28(10), 1577-1580 (2014-05-21)
The present study aims to investigate the influence of irinotecan's toxicity by the biotransformation of glucoaurantio-obtusin to aurantio-obtusin. Intraperitoneal administration (i.p.) of 100 mg/kg aurantio-obtusin significantly increased the toxicity of irinotecan, but the i.p. administration of 100 mg/kg glucoaurantio-obtusin showed
Lauriane Goldwirt et al.
Cancer chemotherapy and pharmacology, 74(1), 185-193 (2014-05-29)
Glioblastoma (GBM), the most common primary brain tumor in adults, is usually rapidly fatal with median survival duration of only 15 months and a 3-year survival rate of <7 %. Temozolomide (TMZ) is the only anticancer drug that has improved
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持